Eseng Lai

2.6k total citations
60 papers, 1.8k citations indexed

About

Eseng Lai is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Eseng Lai has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Molecular Biology and 15 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Eseng Lai's work include Diabetes Treatment and Management (12 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Metabolism, Diabetes, and Cancer (6 papers). Eseng Lai is often cited by papers focused on Diabetes Treatment and Management (12 papers), Pharmacogenetics and Drug Metabolism (7 papers) and Metabolism, Diabetes, and Cancer (6 papers). Eseng Lai collaborates with scholars based in United States, Belgium and Canada. Eseng Lai's co-authors include Gary P. O’Neill, Keith D. Kaufman, Stacy A. Rudnicki, Marek Gawel, Barry W. Festoff, Mike Murphy, F. H. Norris, Deborah Gelinas, Howard M. Natter and R Kratz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neuron and Neurology.

In The Last Decade

Eseng Lai

59 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eseng Lai United States	20	620	474	410	268	260	60	1.8k
Walkyria Oliveira Sampaio Brazil	13	846 1.4×	690 1.5×	252 0.6×	168 0.6×	401 1.5×	20	2.2k
Brent A. McLean Canada	16	570 0.9×	513 1.1×	466 1.1×	50 0.2×	362 1.4×	24	1.6k
Tiziana Bachetti Italy	23	245 0.4×	857 1.8×	202 0.5×	235 0.9×	97 0.4×	56	2.5k
Keiichiro Kataoka Japan	28	375 0.6×	689 1.5×	224 0.5×	93 0.3×	128 0.5×	45	2.1k
Laine J. Murphey United States	24	359 0.6×	325 0.7×	176 0.4×	45 0.2×	241 0.9×	38	1.8k
Tomoya Mita Japan	29	1.6k 2.6×	619 1.3×	632 1.5×	48 0.2×	187 0.7×	109	2.8k
Jasmina Varagić United States	35	821 1.3×	622 1.3×	276 0.7×	49 0.2×	262 1.0×	97	2.7k
Melanie Chin United States	17	265 0.4×	1.0k 2.2×	158 0.4×	66 0.2×	86 0.3×	59	1.9k
Gert M. Kostner Austria	31	539 0.9×	501 1.1×	986 2.4×	58 0.2×	260 1.0×	61	2.5k
Michael J. Mihm United States	14	723 1.2×	740 1.6×	375 0.9×	90 0.3×	153 0.6×	19	2.1k

Countries citing papers authored by Eseng Lai

Since Specialization

Citations

This map shows the geographic impact of Eseng Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eseng Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eseng Lai more than expected).

Fields of papers citing papers by Eseng Lai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eseng Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eseng Lai. The network helps show where Eseng Lai may publish in the future.

Co-authorship network of co-authors of Eseng Lai

This figure shows the co-authorship network connecting the top 25 collaborators of Eseng Lai. A scholar is included among the top collaborators of Eseng Lai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eseng Lai. Eseng Lai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nussbaum, Jesse C., Radha Railkar, Jeffrey R. Sachs, et al.. (2023). Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults. Vaccine. 41(44). 6488–6501. 12 indexed citations

Vanhoutte, Frédéric, Wen Liu, Richard T. Wiedmann, et al.. (2022). Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial. EBioMedicine. 75. 103811–103811. 18 indexed citations

Aliprantis, Antonios O., Christine A. Shaw, Paul Griffin, et al.. (2020). A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines & Immunotherapeutics. 17(5). 1248–1261. 111 indexed citations

Gantz, Ira, Taro Okamoto, Yuka Ito, et al.. (2017). A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. Diabetes Therapy. 8(4). 793–810. 5 indexed citations

Gibson, Christopher R., Ping Lü, Zoe Barter, et al.. (2013). Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica. 43(12). 1027–1036. 15 indexed citations

Dallob, Aimée, Wen‐Lin Luo, Amy O. Johnson‐Levonas, et al.. (2011). The effects of laropiprant, a selective prostaglandin D₂receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets. 22(7). 495–503. 8 indexed citations

Reitman, Marc L., Victor Dishy, William S. Denney, et al.. (2011). Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients. The Journal of Clinical Pharmacology. 52(9). 1306–1316. 38 indexed citations

Radziszewski, Waldemar, Eseng Lai, Mark Stroh, et al.. (2010). A Single Supratherapeutic Dose of Rolofylline Does Not Prolong the QTcF Interval in Healthy Volunteers. American Journal of Therapeutics. 17(1). 8–16. 1 indexed citations

Stroh, Mark, Victor Dishy, Waldemar Radziszewski, et al.. (2010). The Effects of Multiple Doses of Rolofylline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Subjects. American Journal of Therapeutics. 17(1). 53–60. 3 indexed citations

10.

Schwartz, Jules I., Mark Stroh, Bing Gao, et al.. (2009). Effects of Laropiprant, a Selective Prostaglandin D₂ Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone. Cardiovascular Therapeutics. 27(4). 239–245. 4 indexed citations

11.

Schwartz, Jules I., Fang Liu, Yinghong Wang, et al.. (2009). Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women. American Journal of Therapeutics. 16(6). 487–495. 2 indexed citations

12.

Philip, George, Janet van Adelsberg, Tom Loeys, et al.. (2009). Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. Journal of Allergy and Clinical Immunology. 124(5). 942–948.e9. 47 indexed citations

13.

Schwartz, Jules I., Fang Liu, Mark Stroh, et al.. (2009). Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin. American Journal of Therapeutics. 16(3). 215–223. 4 indexed citations

14.

Dishy, Victor, Fang Liu, David L. Ebel, et al.. (2009). Effects of Aspirin When Added to the Prostaglandin D₂ Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms. The Journal of Clinical Pharmacology. 49(4). 416–422. 16 indexed citations

15.

Paolini, John F., Yale Mitchel, Rafael Reyes, et al.. (2008). Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial. International Journal of Clinical Practice. 62(6). 896–904. 14 indexed citations

16.

Hecken, A. Van, Inge De Lepeleire, Chau Thach, et al.. (2007). The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers. European Journal of Clinical Pharmacology. 63(2). 135–141. 29 indexed citations

17.

Paolini, John F., Yale Mitchel, Robert Reyes, et al.. (2007). Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.. The American Journal of Cardiology. 101(5). 625–630. 128 indexed citations

18.

Lai, Eseng, Inge De Lepeleire, Fang Liu, et al.. (2007). Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist. Clinical Pharmacology & Therapeutics. 83(6). 840–847. 41 indexed citations

19.

Karanam, Bindhu V., Maria Madeira, Scott A. Bradley, et al.. (2007). Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans. Drug Metabolism and Disposition. 35(7). 1196–1202. 24 indexed citations

20.

Na, Erqian, Maria McCarthy, Christine Neyt, Eseng Lai, & Gord Fishell. (1998). Telencephalic progenitors maintain anteroposterior identities cell autonomously. Current Biology. 8(17). 987–S2. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact